Sanofi-Aventis and Regeneron begin phase 3 trials of cancer drug |
|
|
|
Published
:
Thu, 23 Aug 2007 12:46
|
PARIS (Thomson Financial) - Sanofi-Aventis and Regeneron Pharmaceuticals Inc have begun two phase 3 trials of a jointly-developed drug on patients with prostate cancer and non-small cell lung cancer.Aflibercept is an anti-angiogenic agent targeting Vascular Endothelial Growth Factor (VEGF). It is designed to be used in conjunction with chemotherapy regimens.The two trials will be double-blind and placebo-controlled, Regeneron said.Sanofi-Aventis will provide an update of the broad-based clinical development programme planned for the drug as well as further details on the trials at its research and development day on September 17.Sanofi-Aventis said in June it would start seeking regulatory approval as early as next year to market the drug.helen.beresford@thomson.comhem/jlcCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2374.41 |
-16.87 (
-0.71 %)
|
| SYMBOL (
2010-03-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
12:35pm )
|
|
2650.00 |
+52.00 (
2.00 %)
|
|
WHITBREAD
(
12:35pm )
|
|
1540.00 |
+21.00 (
1.37 %)
|
| SYMBOL (
2010-03-19 )
|
| LAST |
CHANGE
|
| SYMBOL (
2010-03-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Novo Nordisk sues Sanofi-Aventis for patent infringement UPDATE 